Samsung Biologics Reports Third Quarter 2026 Financial Results
Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.